Neurotrophin 3 Shows Promise in CMT

MDA Research News has a short article about the success of NT3 for nerve regeneration in a small study of CMT1A patients. Again, this isn’t specific to Dejerine-Sottas, but may turn out to be applicable for future research.

A pilot study of eight people with Charcot-Marie-Tooth (CMT) disease, a disorder in which signals in the peripheral nervous system are impaired, has found that treatment with neurotrophin 3 (NT3) improved sensory function and nerve regeneration.

Leave a Reply

Your email address will not be published. Required fields are marked *